Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial. (24th October 2019)
- Record Type:
- Journal Article
- Title:
- Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial. (24th October 2019)
- Main Title:
- Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial
- Authors:
- Nochioka, Kotaro
Sakata, Yasuhiko
Miura, Masanobu
Shiroto, Takashi
Takahashi, Jun
Saga, Chie
Ikeno, Yasuko
Shiba, Nobuyuki
Shinozaki, Tsuyoshi
Sugi, Masafumi
Nakagawa, Makoto
Komaru, Tatsuya
Kato, Atsushi
Nozaki, Eiji
Iwabuchi, Kaoru
Hiramoto, Tetsuya
Inoue, Kanichi
Ohe, Masatoshi
Tamaki, Kenji
Tsuji, Ichiro
Shimokawa, Hiroaki - Abstract:
- Abstract: Aims: The study aims to evaluate the prognostic significance of impaired glucose tolerance (IGT) with reference to albuminuria in patients with chronic heart failure (CHF). Methods and results: We examined 535 CHF patients (mean 66 years, women 25%) in the control arm of our SUPPORT trial, in which we examined additive impact of olmesartan in hypertensive patients with symptomatic CHF treated with β‐blockers and/or angiotensin‐converting enzyme inhibitors. We examined the association between glycaemic abnormality (assessed by 75 g of oral glucose tolerance test) and albuminuria for a composite outcome of all‐cause death, myocardial infarction, stroke, and HF hospitalization. IGT patients ( N = 113, mean 67.2 years) were older and more frequently treated with β‐blockers compared with those with normal glucose regulation ( N = 142, mean 64.0 years) and those with diabetes mellitus ( N = 280, mean 65.7 years). Multivariable Cox proportional hazard models revealed that, as compared with normal glucose regulation (NGR), IGT was associated with increased risk of the outcome when complicated by albuminuria [hazard ratio (HR) 2.25; 95% confidence interval (CI) 1.14–4.42; P = 0.019] but not when uncomplicated by albuminuria (HR 0.76; 95% CI 0.35–1.60, P = 0.47) ( P for interaction = 0.041). This was also the case for diabetes mellitus and albuminuria (HR 2.06; 95% CI 1.17–3.61; P = 0.012). Among IGT patients without albuminuria, 21 (29%) developed albuminuria atAbstract: Aims: The study aims to evaluate the prognostic significance of impaired glucose tolerance (IGT) with reference to albuminuria in patients with chronic heart failure (CHF). Methods and results: We examined 535 CHF patients (mean 66 years, women 25%) in the control arm of our SUPPORT trial, in which we examined additive impact of olmesartan in hypertensive patients with symptomatic CHF treated with β‐blockers and/or angiotensin‐converting enzyme inhibitors. We examined the association between glycaemic abnormality (assessed by 75 g of oral glucose tolerance test) and albuminuria for a composite outcome of all‐cause death, myocardial infarction, stroke, and HF hospitalization. IGT patients ( N = 113, mean 67.2 years) were older and more frequently treated with β‐blockers compared with those with normal glucose regulation ( N = 142, mean 64.0 years) and those with diabetes mellitus ( N = 280, mean 65.7 years). Multivariable Cox proportional hazard models revealed that, as compared with normal glucose regulation (NGR), IGT was associated with increased risk of the outcome when complicated by albuminuria [hazard ratio (HR) 2.25; 95% confidence interval (CI) 1.14–4.42; P = 0.019] but not when uncomplicated by albuminuria (HR 0.76; 95% CI 0.35–1.60, P = 0.47) ( P for interaction = 0.041). This was also the case for diabetes mellitus and albuminuria (HR 2.06; 95% CI 1.17–3.61; P = 0.012). Among IGT patients without albuminuria, 21 (29%) developed albuminuria at 1‐year visit, which was again associated with poor prognosis (HR 7.36; 95% CI 1.39–38.98, P = 0.019). Conclusions: These results indicate that IGT is associated with poor prognosis when complicated by albuminuria in CHF patients, demonstrating the importance of combined early stages of glucose intolerance and renal dysfunction in the management of CHF. … (more)
- Is Part Of:
- ESC heart failure. Volume 6:Number 6(2019)
- Journal:
- ESC heart failure
- Issue:
- Volume 6:Number 6(2019)
- Issue Display:
- Volume 6, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 6
- Issue:
- 6
- Issue Sort Value:
- 2019-0006-0006-0000
- Page Start:
- 1252
- Page End:
- 1261
- Publication Date:
- 2019-10-24
- Subjects:
- Chronic heart failure -- Impaired glucose tolerance -- Diabetes mellitus -- Albuminuria
Heart failure -- Periodicals
616.129005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2055-5822 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ehf2.12516 ↗
- Languages:
- English
- ISSNs:
- 2055-5822
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 12640.xml